Please assess the completion status of the following clinical trial:

Trial Title: Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Self-reported cough (\> 8 weeks), with cough VAS ≥ 30/100~2. A diagnosis of IPF within 5 years prior to the screening visit, as per applicable ATS/ERS/JRS/ALAT guidelines, in line with hospital records.~3. Age 3.1. Male and female participants aged ≥ 40 - 90 years at the time of signing informed consent~4. Sex:~   4.1 Male participants: A male participant must agree to use contraception as detailed in Appendix 2 of this protocol during the study and for at least 90 days after the follow-up visit, and refrain from donating sperm during this period 4.2 Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP)~5. Meeting all of the following criteria during the screening period: FVC ≥ 45% predicted of normal, Forced expiratory volume in 1 second (FEV1)/FVC ≥0.7, DLCO corrected for Hb ≥30% predicted of normal.~6. The extent of fibrotic changes is greater than the extent of emphysema on the most recent HRCT scan (investigator determined within 24 months of the study screening visit)~7. Written informed consent.~Exclusion criteria:~1. Treatment with immunosuppressive therapy or antibiotics within last 4 weeks. A stable dose of corticosteroids equivalent to prednisolone of 10 mg per day or less, if used for an indication other than pulmonary disease will be permitted~2. Current smoker~3. History of alcohol and drug(s) addiction~4. Regular use of sedative therapies~5. Acute IPF exacerbation within 6 months prior to screening and/or during the screening period.~6. Concurrent use of pirfenidone or Nintedanib, unless receiving a stable dose for at least 8 weeks prior to screening~7. Use of ACE inhibitors~8. Patients with co-existent conditions know to be associated with the development of fibrotic lung disease. This includes: connective tissue disease, (plural plaques, mesothelioma), granulomatous disease including sarcoidosis. Patient with auto-immune profile considered diagnostic for a specific connective tissue disease will be excluded, even in the absence of systemic symptoms. Non-specific rises in auto antibodies e.g. rheumatoid factors, anti-nuclear antibody etc. will not be used to exclude individuals from the study.~9. Significant other organ co-morbidity including hepatic or renal impairment and pulmonary hypertension (investigator determined).~10. Significant coronary artery disease (myocardial infarction within 6 months or ongoing unstable angina within 4 weeks of screening visit) or congestive cardiac failure based on clinical examination~11. Patients as significant risk of side effects, intolerance or allergy to morphine~12. Pregnant and breastfeeding patients, or women or child-bearing potential, not using a reliable contraceptive method (see Appendix 2). A urine pregnancy test will be performed in females of child-bearing potential at the initial study visit.~13. Unable to provide informed written consent~14. Predicted life expectancy \< 6 months~15. Use of long-term oxygen therapy. Use of ambulatory oxygen will be permitted.~16. Current or use of opiates within 14 days of the screening visit.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Morphine Sulfate (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).